A Phase I Trial of the IGF‐1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer

PURPOSE. This study evaluated the maximum tolerated dose or recommended phase II dose (RPTD) and safety and tolerability of the ganitumab and everolimus doublet regimen followed by the ganitumab, everolimus, and panitumumab triplet regimen. MATERIALS AND METHODS. This was a standard 3 + 3 dose escal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Vlahovic, Gordana, Meadows, Kellen L., Hatch, Ace J., Jia, Jingquan, Nixon, Andrew B., Uronis, Hope E., Morse, Michael A., Selim, M. Angelica, Crawford, Jeffrey, Riedel, Richard F., Zafar, S. Yousuf, Howard, Leigh A., O'Neill, Margot, Meadows, Jennifer J., Haley, Sherri T., Arrowood, Christy C., Rushing, Christel, Pang, Herbert, Hurwitz, Herbert I.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058343/
https://ncbi.nlm.nih.gov/pubmed/29572245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0377
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados